OraSure Technologies (NASDAQ:OSUR) Director Steven Kyle Boyd Purchases 25,000 Shares of Stock

OraSure Technologies, Inc. (NASDAQ:OSUR) Director Steven Kyle Boyd purchased 25,000 shares of the business’s stock in a transaction dated Thursday, May 14th. The shares were acquired at an average price of $2.99 per share, for a total transaction of $74,750.00. Following the acquisition, the director directly owned 113,462 shares in the company, valued at $339,251.38. This represents a 28.26% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Steven Kyle Boyd also recently made the following trade(s):

• On Tuesday, May 12th, Steven Kyle Boyd acquired 25,000 shares of OraSure Technologies stock. The stock was acquired at an average cost of $2.98 per share, with a total value of $74,500.00.

OraSure Technologies Trading Down 3.0%

Shares of NASDAQ:OSUR opened at $2.95 on Friday. The stock has a market capitalization of $203.11 million, a PE ratio of -2.84 and a beta of 0.89. OraSure Technologies, Inc. has a 1 year low of $2.08 and a 1 year high of $3.82. The firm has a fifty day moving average price of $3.06 and a 200 day moving average price of $2.76.

OraSure Technologies (NASDAQ:OSUR) last posted its earnings results on Wednesday, February 25th. The medical instruments supplier reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.02). The company had revenue of $26.76 million for the quarter, compared to the consensus estimate of $26.44 million. OraSure Technologies had a negative net margin of 66.42% and a negative return on equity of 18.57%.

Institutional Investors Weigh In On OraSure Technologies

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Amundi acquired a new position in shares of OraSure Technologies during the 1st quarter worth about $47,000. AQR Capital Management LLC grew its holdings in OraSure Technologies by 48.3% in the 1st quarter. AQR Capital Management LLC now owns 1,041,875 shares of the medical instruments supplier’s stock valued at $3,511,000 after buying an additional 339,493 shares during the last quarter. NewEdge Advisors LLC increased its position in OraSure Technologies by 32,595.9% in the 1st quarter. NewEdge Advisors LLC now owns 47,736 shares of the medical instruments supplier’s stock worth $161,000 after buying an additional 47,590 shares during the period. Empowered Funds LLC lifted its holdings in shares of OraSure Technologies by 7.2% during the first quarter. Empowered Funds LLC now owns 405,216 shares of the medical instruments supplier’s stock worth $1,366,000 after buying an additional 27,310 shares during the last quarter. Finally, Envestnet Asset Management Inc. lifted its holdings in shares of OraSure Technologies by 32.7% during the second quarter. Envestnet Asset Management Inc. now owns 33,018 shares of the medical instruments supplier’s stock worth $99,000 after buying an additional 8,133 shares during the last quarter. 93.50% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded OraSure Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, May 7th. Two equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Reduce” and an average target price of $3.00.

OraSure Technologies Company Profile

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.